The 14th Cancer Crosslinks: Save-the-Date
Thursday, January 27, 2022, 11:30-16:15 CET
Join distinguished speakers from the UK, USA, Germany, Switzerland, Canada, and Norway as they discuss recent progress in the understanding of tumor evolution and emerging diagnostic and treatment options for solid and hematological cancers.
Cancer Crosslinks 2022 will be a Digital Meeting streamed from Oslo Cancer Cluster Innovation Park. There will be an option to attend on-site pending COVID-19 guidelines. More information will be available on the registration page (opening October 2021).
Cancer Crosslinks 2022 will be a Digital Meeting streamed from Oslo Cancer Cluster Innovation Park. There will be an option to attend on-site pending COVID-19 guidelines. More information will be available on the registration page (opening October 2021).
Event 2022 - International Speakers
Mariam Jamal-Hanjani, Group Leader, Cancer Metastasis Lab, CRUK Lung Cancer Centre of Excellence, UCL Cancer Institute. Senior Clinical Lecturer and Honorary Consultant in Translational Lung Oncology, UCL Hospital. Visiting Scientist, The Francis Crick Institute, London, UK
David Rimm, Anthony N. Brady Professor of Pathology, Professor of Medicine (Oncology),
Director, Translational Pathology and Director, Yale Pathology Tissue Services; Director, Physician Scientist Training Program in Pathology, Yale University School of Medicine, New Haven, USA
Martin Schuler, Professor, Director Department of Medical Oncology, University Hospital Essen; Spokesman for the German Cancer Consortium (DKTK), Partner Site University Hospital,
Essen, Germany
Angela George, Clinical Director of Genomics and Consultant Medical Oncologist in Gynecology,
Royal Marsden Hospital, London, UK
Christoph Driessen, Professor, Head of Clinical Trial Unit, Department of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Bertrand Routy, Assistant Professor of Hemato-Oncology, Centre de recherche,
Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Canada
David Rimm, Anthony N. Brady Professor of Pathology, Professor of Medicine (Oncology),
Director, Translational Pathology and Director, Yale Pathology Tissue Services; Director, Physician Scientist Training Program in Pathology, Yale University School of Medicine, New Haven, USA
Martin Schuler, Professor, Director Department of Medical Oncology, University Hospital Essen; Spokesman for the German Cancer Consortium (DKTK), Partner Site University Hospital,
Essen, Germany
Angela George, Clinical Director of Genomics and Consultant Medical Oncologist in Gynecology,
Royal Marsden Hospital, London, UK
Christoph Driessen, Professor, Head of Clinical Trial Unit, Department of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Bertrand Routy, Assistant Professor of Hemato-Oncology, Centre de recherche,
Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Canada
Event 2022 - Topics
Tracking Lung Cancer Evolution from Early to Late-Stage Disease - Its Clinical
and Therapeutic Implications, Mariam Jamal-Hanjani, UCL Cancer Institute London, UK
Current and Future Methods of Predicting Response to Immunotherapy,
David Rimm, Yale University School of Medicine, New Haven, USA
Immunotherapy Trials in the Perioperative Setting - Opportunity for Clinical Proof-of-Concept
and Mechanistic Exploration, Martin Schuler, Partner Site University Hospital Essen, Germany
Precision Therapy for Gynecological Cancers with Focus on Endometrial
(Uterine) Cancer – Molecular Subtypes & Emerging Treatment Options,
Angela George, Royal Marsden Hospital, London, UK
Advances in Multiple Myeloma Treatment Using Proteasome Inhibitors
(The Proteasome and Proteasome Inhibitors: From Biology to Clinical Impact),
Christoph Driessen, Kantonsspital St. Gallen, St Gallen, Switzerland
Gut Microbiome in the Immunotherapy Arena: From Biomarker to Therapeutics,
Bertrand Routy, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Canada
and Therapeutic Implications, Mariam Jamal-Hanjani, UCL Cancer Institute London, UK
Current and Future Methods of Predicting Response to Immunotherapy,
David Rimm, Yale University School of Medicine, New Haven, USA
Immunotherapy Trials in the Perioperative Setting - Opportunity for Clinical Proof-of-Concept
and Mechanistic Exploration, Martin Schuler, Partner Site University Hospital Essen, Germany
Precision Therapy for Gynecological Cancers with Focus on Endometrial
(Uterine) Cancer – Molecular Subtypes & Emerging Treatment Options,
Angela George, Royal Marsden Hospital, London, UK
Advances in Multiple Myeloma Treatment Using Proteasome Inhibitors
(The Proteasome and Proteasome Inhibitors: From Biology to Clinical Impact),
Christoph Driessen, Kantonsspital St. Gallen, St Gallen, Switzerland
Gut Microbiome in the Immunotherapy Arena: From Biomarker to Therapeutics,
Bertrand Routy, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Canada
Event 2022 - Moderators from Norway
Kristina Lindemann, Head of Research, Dept. of Gynecological Oncology, Oslo University Hospital
Åsmund Flobak, St. Olavs Hospital, Trondheim University Hospital
Tobias Schmidt Slørdahl, St. Olavs Hospital, Trondheim University Hospital
Åsmund Flobak, St. Olavs Hospital, Trondheim University Hospital
Tobias Schmidt Slørdahl, St. Olavs Hospital, Trondheim University Hospital
Event 2022 - Reference Materials
|
Organizer
|
Sponsors 2022
|
|
|
|
To learn more about previous Cancer Crosslinks events, visit the GALLERY.